Bora CDMO Bora CDMO

X

Find Drugs in Development News & Deals for Cetrorelix

PharmaCompass
API SUPPLIERS
API Suppliers

API Suppliers

US DMFs Filed

US DMFs Filed

CEP/COS Certifications

CEP/COS Certifications

0

JDMFs Filed

JDMFs Filed

Other Certificates

Other Certificates

Other Suppliers

Other Suppliers

API REF. PRICE (USD / KG)
INTERMEDIATES

0

DOSSIERS // FDF
USA (Orange Book)

USA (Orange Book)

Europe

Europe

Canada

Canada

Australia

Australia

South Africa

South Africa

Uploaded Dossiers

Uploaded Dossiers

GLOBAL SALES (USD Million)

U.S. Medicaid

0

Annual Reports

0

EXCIPIENTS

0

PATENTS & EXCLUSIVITIES

USFDA Orange Book Patents

0

USFDA Exclusivities

0

DIGITAL CONTENT

Blog #PharmaFlow

News

REF STANDARD

EDQM

0

USP

0

JP

0

Other Listed Suppliers

SERVICES

0

left grey arrow
right gray arrow
  • POWDER;SUBCUTANEOUS - EQ 0.25MG BASE/VIAL
  • POWDER;SUBCUTANEOUS - EQ 3MG BASE/VIAL

Details:

Cetrorelix Acetate is used to prevent premature ovulation during controlled ovarian stimulation. Cetrorelix blocks the effects of a natural hormone, called GnRH. GnRH controls the secretion of another hormone, called LH, which induces ovulation during the menstrual cycle.


Lead Product(s): Cetrorelix Acetate

Therapeutic Area: Obstetrics/Gynecology (Women’s Health) Product Name: Cetrorelix Acetate-Generic

Highest Development Status: ApprovedProduct Type: Large molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable October 27, 2022

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content

Details:

Provepharm acquired global rights of the Cetrorelix acetate from Calyptus and will take on all development activities and ultimately commercial distribution upon approval.


Lead Product(s): Cetrorelix Acetate

Therapeutic Area: Obstetrics/Gynecology (Women’s Health) Product Name: Cetrorelix Acetate-Generic

Highest Development Status: ApprovedProduct Type: Large molecule

Partner/Sponsor/Collaborator: Provepharm Life Solutions

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Partnership August 22, 2022

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content

Details:

Cetrorelix Acetate for Injection, 0.25 mg/vial is indicated for the inhibition of premature luteinizing hormone surges in women undergoing controlled ovarian stimulation.


Lead Product(s): Cetrorelix Acetate

Therapeutic Area: Obstetrics/Gynecology (Women’s Health) Product Name: Cetrorelix Acetate-Generic

Highest Development Status: ApprovedProduct Type: Large molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable August 19, 2022

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content

Details:

Cetrorelix Acetate for Injection 0.25 mg is used to prevent premature ovulation during controlled ovarian stimulation, for Injection blocks such undesirable premature ovulation.


Lead Product(s): Cetrorelix Acetate

Therapeutic Area: Obstetrics/Gynecology (Women’s Health) Product Name: Cetrorelix Acetate-Generic

Highest Development Status: ApprovedProduct Type: Large molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable August 16, 2022

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty
Post Enquiry
POST ENQUIRY